Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115492 · ClinicalTrials.gov registry record · Phase 4
Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
A Phase 4 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 797
- Enrollment target
- 20
- Study locations
NCT00115492: Completed Phase 4 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
NCT00115492 is a Phase 4 study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 797 participants, below the 1,033-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (23% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00115492, a Phase 4 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 797 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All study related medicines and medical examinations will be provided at no cost. The two drugs used in this study have been approved by FDA for use in patients with COPD.
Conditions Studied
Interventions
- DRUG Salmeterol
- DRUG Fluticasone Propionate/Salmeterol Combination Product
Study Locations (20)
Florida
- GSK Investigational Site - Atlantis
- GSK Investigational Site - Clearwater
- GSK Investigational Site - DeLand
- GSK Investigational Site - Fort Lauderdale
- GSK Investigational Site - Pensacola
- GSK Investigational Site - Sarasota
- GSK Investigational Site - Tamarac
California
- GSK Investigational Site - Berkeley
- GSK Investigational Site - Fullerton
- GSK Investigational Site - Riverside
- GSK Investigational Site - Sacramento
- GSK Investigational Site - San Diego
- GSK Investigational Site - Vista
Alabama
- GSK Investigational Site - Jasper
- GSK Investigational Site - Mobile
Arizona
- GSK Investigational Site - Glendale
- GSK Investigational Site - Phoenix
Colorado
- GSK Investigational Site - Fort Collins
Connecticut
- GSK Investigational Site - Stamford
Georgia
- GSK Investigational Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 797 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 4 |
What the finished NCT00115492 record still lists
NCT00115492 is an interventional study that assigns participants to a tested intervention. The registered 797 participants enrollment target is mid-sized for trials with a published cap, below the 1,033-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Salmeterol is the first listed.
NCT00115492 names 20 study sites across 7 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00115492 about?
NCT00115492 is a clinical study titled "Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations". This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All ...
What is the current status of trial NCT00115492?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 797 participants. The study started on 2004-12. Estimated completion is 2007-06.
What conditions does trial NCT00115492 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00115492?
The interventions under investigation include: Salmeterol (DRUG), Fluticasone Propionate/Salmeterol Combination Product (DRUG).
Who is sponsoring clinical trial NCT00115492?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00115492 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00115492's enrollment target sits among peer trials
797 21st of 74 higher than 54 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients
COMPLETED · Phase 4
-
Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD
COMPLETED · Phase 4
-
Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
COMPLETED · Phase 4
-
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
COMPLETED · Phase 4
-
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
COMPLETED · Phase 4
-
Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06051058 · 798 participants · NA
Care Transitions App for Patients With Multiple Chronic Conditions
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia